Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates

• Published in: Vox sanguinis Vol. 100; no. 4; pp. 351 - 358
• Main Authors: Modrow, S., Wenzel, J. J., Schimanski, S., Schwarzbeck, J., Rothe, U., Oldenburg, J., Jilg, W., Eis-Hübinger, A. M.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-05-2011; S. Karger AG
• Subjects: Blood clots; Blood Component Transfusion; Blood products; Coagulation factors; Data processing; Disease resistance; DNA viruses; DNA, Viral - blood; Genomes; Genotypes; Hepatitis; Hepatitis A; Hepatitis A - blood; Hepatitis A - prevention & control; Hepatitis A - transmission; Hepatitis A virus; Hepatitis A Virus, Human; Hepatitis E - blood; Hepatitis E - prevention & control; Hepatitis E - transmission; Hepatitis E virus; hepatitis virus; human bocavirus; Humans; iatrogenic transmission; nucleic acids; Parvoviridae Infections - blood; Parvoviridae Infections - prevention & control; Parvoviridae Infections - transmission; Parvovirus; Parvovirus B19; plasma-derived coagulation factor products; Polymerase chain reaction; Polymerase Chain Reaction - methods; prothrombin; recombinant coagulation factor products; RNA, Viral - blood; Viruses
• ISSN: 0042-9007; 1423-0410
• DOI: 10.1111/j.1423-0410.2010.01445.x

Background and Objectives  Due to their high resistance to inactivation procedures, nonenveloped viruses such as parvovirus B19, human bocavirus (HBoV), human parvovirus 4 (PARV4), hepatitis A (HAV) and hepatitis E virus (HEV) pose a particular threat to blood products. Virus transmission to patients treated with blood products presents an additional burden to disease. We determined the frequency and the amount of nucleic acid specific for nonenveloped viruses in recently manufactured preparations of commercial coagulation factor concentrates.
Materials and Methods  At least three different batches of each of 13 different plasma‐derived and recombinant coagulation factor products were tested for the presence and the amount of nucleic acid for parvovirus B19, HBoV, human parvovirus 4, hepatitis A virus and HEV by using quantitative polymerase chain reaction.
Results  Whereas none of the recombinant products tested positive for any of these viruses, parvovirus B19 DNA with amounts ranging between 2 × 101 and 1.3 × 103 genome equivalents/ml was detected in five plasma‐derived products. In addition to parvovirus B19 genotype 1, genotypes 2 and 3 were observed in two batches of a factor VIII/von‐Willebrand factor product. In two products (one factor VIII concentrate and one activated prothrombin complex concentrate), a combination of both genotypes 1 and 2 of parvovirus B19 was detected.
Conclusion  The data show that nucleic acids from several relevant nonenveloped viruses are not found at detectable levels in coagulation factor concentrates. In some cases, parvovirus B19 DNA was detectable at low levels. Testing of the plasma pools for the full range of parvovirus genotypes is advocated for ensuring product safety.